Maduck Sean's Form 4 filing
Corcept Therapeutics Inc (CORT) · filed Sep 6, 2022
- Accession no.
- 0000899243-22-030515
- Filed
- Sep 6, 2022
- Trade date
- Sep 1, 2022
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $646.0K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maduck SeanCIK 0001698310 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2022 | Common Stock | MOption exerciseAcquired | +25,000 | $3.29 | +$82,250 | 79,618 | Direct | |
| Sep 1, 2022 | Common Stock | SSaleDisposed | −25,000 | $25.84F2 | −$646,000 | 54,618 | Direct | |
| Sep 1, 2022 | Common Stock | AGrant or awardAcquired | +922 | $25.98F4 | +$23,953.56 | 55,540 | Direct | |
| Sep 1, 2022 | Common Stock | AGrant or awardAcquired | +922 | $0.00 | $0 | 56,462 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2022 | Common Stock | MOption exerciseDisposed | −15,000 | $0.00 | $0 | 82,602 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $25.82 to $25.94. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F4
In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
Referenced by the price of 1 transaction in Table I.
Remarks
President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.